clinical trial · NCT06356194
Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
Healthy Volunteer StudyCohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIKCohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered.
brief summary
Drug-drug interaction study of Biktarvy and Bemnifosbuvir/Ruzasvir
started
Apr 15, 2024
primary completion
May 30, 2024
completion
May 30, 2024
last updated
Jul 31, 2024
official title
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Drug-Drug Interaction Potential Between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy®) in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol